Table 1.

Results of placebo controlled randomised trials of drotrecogin alfa (activated)

Trial	Actual/Planned recruitment	% of planned recruitment	% Assigned DAA who Died	% Assigned Placebo who Died	RR DAA vs. Placebo	95% CI for RR
PROWESS All patients	1,690/2,280	74.1%	24.7%	30.8%	0.80	0.69–0.94
PROWESS APACHE II < 25	873	NA	18.8	19.0	0.99	0.75–1.30
PROWESS APACHE II > 24	817	NA	30.9%	43.7%	0.71	0.59–0.85
PROWESS single organ failure	418	NA	19.5%	21.2%	0.92	0.63–1.35
PROWESS > 1 organ failure	1,271	NA	26.5%	33.9%	0.78	0.66–0.93
ADDRESS: All patients	2,640/11,444	23.1%	18.5%	17.0%	1.09	0.92–1.28
ADDRESS APACHE II > 24	321	NA	29.5%	24.7%	1.22	0.85–1.74
ADDRESS > 1 Organ failure	862	NA	20.7%	21.9%	0.94	0.73–1.22
RESOLVE	477/6,000	8.0%	17.2%	17.5%	0.98	0.66–1.46

DAA Drotrecogin alfa (activated), RR relative risk, 95% CI = 95% confidence interval, NA not applicable